Adam W Carrico1, Steven Shoptaw, Christopher Cox, Ronald Stall, Xiuhong Li, David G Ostrow, David Vlahov, Michael W Plankey. 1. *Department of Community Health Systems, School of Nursing, University of California, San Francisco, CA; †Departments of Family Medicine and Psychiatry, David Geffen School of Medicine, University of California, Los Angeles, CA; ‡Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD; §Department of Behavioral and Community Health Sciences, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; ‖The Chicago MACS and Ostrow & Associates, LLC, Chicago, IL; and ¶Division of Infectious Diseases, Department of Medicine, Georgetown University Medical Center, Washington, DC.
Abstract
BACKGROUND: HIV-positive persons who use stimulants (eg, methamphetamine) experience profound health disparities, but it remains unclear whether these persist after highly active antiretroviral therapy (HAART) initiation. Conducted within the Multicenter AIDS Cohort Study, this investigation examined whether stimulant use is associated with progression to AIDS or all-cause mortality after the initiation of HAART. METHODS: Using marginal structural modeling, the cumulative proportion of visits where any stimulant use was reported (ie, 0%, 1%-49%, 50%-99%, and 100%) was examined as a time-varying predictor of (1) all-cause mortality and (2) AIDS or all-cause mortality. RESULTS: Among the 1313 men who have sex with men (MSM) who initiated HAART, findings showed no significant association of any level of stimulant use with all-cause mortality. A competing risk analysis indicated that no level of stimulant use was associated with increased AIDS-related or non-AIDS mortality separately. Among the 648 participants without AIDS at HAART initiation, a secondary analysis indicated that stimulant use at 50% or more of study visits was associated with a 1.5-fold increase in the odds of progression to AIDS or all-cause mortality (adjusted odds ratio = 1.54; 95% confidence interval: 1.02 to 2.33; P < 0.05). CONCLUSIONS: HIV-positive stimulant-using MSM receiving HAART seem to face no greater overall risks for all-cause, AIDS-related, or non-AIDS mortality compared with nonusers. However, men without AIDS at HAART initiation who more frequently reported stimulant use demonstrated modestly increased odds of progression to AIDS or all-cause mortality. Comprehensive approaches are needed to optimize the effectiveness of HAART with stimulant-using MSM.
BACKGROUND: HIV-positive persons who use stimulants (eg, methamphetamine) experience profound health disparities, but it remains unclear whether these persist after highly active antiretroviral therapy (HAART) initiation. Conducted within the Multicenter AIDS Cohort Study, this investigation examined whether stimulant use is associated with progression to AIDS or all-cause mortality after the initiation of HAART. METHODS: Using marginal structural modeling, the cumulative proportion of visits where any stimulant use was reported (ie, 0%, 1%-49%, 50%-99%, and 100%) was examined as a time-varying predictor of (1) all-cause mortality and (2) AIDS or all-cause mortality. RESULTS: Among the 1313 men who have sex with men (MSM) who initiated HAART, findings showed no significant association of any level of stimulant use with all-cause mortality. A competing risk analysis indicated that no level of stimulant use was associated with increased AIDS-related or non-AIDS mortality separately. Among the 648 participants without AIDS at HAART initiation, a secondary analysis indicated that stimulant use at 50% or more of study visits was associated with a 1.5-fold increase in the odds of progression to AIDS or all-cause mortality (adjusted odds ratio = 1.54; 95% confidence interval: 1.02 to 2.33; P < 0.05). CONCLUSIONS: HIV-positive stimulant-using MSM receiving HAART seem to face no greater overall risks for all-cause, AIDS-related, or non-AIDS mortality compared with nonusers. However, men without AIDS at HAART initiation who more frequently reported stimulant use demonstrated modestly increased odds of progression to AIDS or all-cause mortality. Comprehensive approaches are needed to optimize the effectiveness of HAART with stimulant-using MSM.
Authors: Adam W Carrico; Elise D Riley; Mallory O Johnson; Edwin D Charlebois; Torsten B Neilands; Robert H Remien; Marguerita A Lightfoot; Wayne T Steward; Lance S Weinhardt; Jeffrey A Kelly; Mary Jane Rotheram-Borus; Stephen F Morin; Margaret A Chesney Journal: J Acquir Immune Defic Syndr Date: 2011-02-01 Impact factor: 3.731
Authors: Adam W Carrico; David R Bangsberg; Sheri D Weiser; Maggie Chartier; Samantha E Dilworth; Elise D Riley Journal: AIDS Date: 2011-05-15 Impact factor: 4.177
Authors: Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall Journal: Lancet Date: 2010-07-16 Impact factor: 79.321
Authors: Adam W Carrico; Mallory O Johnson; Stephen F Morin; Robert H Remien; Elise D Riley; Frederick M Hecht; Dietmar Fuchs Journal: Brain Behav Immun Date: 2008-08-03 Impact factor: 7.217
Authors: Krisda H Chaiyachati; Osondu Ogbuoji; Matthew Price; Amitabh B Suthar; Eyerusalem K Negussie; Till Bärnighausen Journal: AIDS Date: 2014-03 Impact factor: 4.177
Authors: Catherine C McGowan; David D Weinstein; Charles P Samenow; Samuel E Stinnette; Gema Barkanic; Peter F Rebeiro; Timothy R Sterling; Richard D Moore; Todd Hulgan Journal: PLoS One Date: 2011-04-25 Impact factor: 3.240
Authors: Adam W Carrico; Walter Gόmez; Jennifer Jain; Steven Shoptaw; Michael V Discepola; David Olem; Justin Lagana-Jackson; Rick Andrews; Torsten B Neilands; Samantha E Dilworth; Jennifer L Evans; William J Woods; Judith T Moskowitz Journal: Drug Alcohol Depend Date: 2018-09-05 Impact factor: 4.492
Authors: Adam W Carrico; Emily M Cherenack; Margaret E Roach; Elise D Riley; Olorunleke Oni; Samantha E Dilworth; Steven Shoptaw; Peter Hunt; Sabita Roy; Suresh Pallikkuth; Savita Pahwa Journal: AIDS Date: 2018-03-27 Impact factor: 4.177
Authors: Richard A Teran; Adam W Carrico; Keith J Horvath; Martin J Downing; Mary Ann Chiasson; Suzan M Walters; Sabina Hirshfield Journal: Arch Sex Behav Date: 2019-10-19
Authors: Adam W Carrico; Peter W Hunt; Torsten B Neilands; Samantha E Dilworth; Jeffrey N Martin; Steven G Deeks; Elise D Riley Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: M Reuel Friedman; Robert W S Coulter; Anthony J Silvestre; Ron Stall; Linda Teplin; Steve Shoptaw; Pamela J Surkan; Michael W Plankey Journal: AIDS Care Date: 2016-07-25